AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02152423
Drug: LOVENOX
RxNorm normalized name: Lovenox
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH
Trial: NCT00878228
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study group will receive 4 mg of IV ondansetron perioperatively and also postoperative oral ondansetron tablets (8 mg each day for two days). The tablets will be concealed in generic capsules prepared by the pharmacy at the Hospital for Special Surgery to make the ondansetron tablets indistinguishable from the placebos.
Trial: NCT00890968
Drug: Triamcinolone Acetonide (TAC) DuraPeel
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical gel; once daily (nightly); total duration: 4 weeks
Trial: NCT02384369
Drug: SNC-102 sustained release tablet
RxNorm normalized name: Immunoglobulin g1-lambda, anti-(homo sapiens snca (synuclein alpha, alpha-synuclein, park1, park4, parkinson disease (autosomal dominant, lewy body) 4, non a4 component of amyloid precursor, nacp)), monoclonal antibodygamma1 heavy chain (1-442) (vh (homo
DrugBank: Cinpanemab (DB16127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release oral tablet of SNC-102
Trial: NCT04799782
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg dose before bed-time
Trial: NCT01065129
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01065129
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01065129
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03596125
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine supplementation
Trial: NCT02781883
Drug: BP1001 in combination with Ventoclax plus decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BP1001 in combination with Ventoclax plus decitabine
Trial: NCT02781883
Drug: BP1001 plus decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BP1001 plus decitabine in ventoclax intolerant or resistant subjects
Trial: NCT03206060
Drug: Lu-177-DOTATATE
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu-177-DOTATATE IV at weeks 1, 8, 16 and 24.
Trial: NCT03206060
Drug: Ga-68-DOTATATE
RxNorm normalized name: dodatate
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ga-68-DOTATATE PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
Trial: NCT03206060
Drug: F-18-FDG
RxNorm normalized name: 18-F FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: F-18-FDG PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
Trial: NCT03206060
Drug: Amino Acid solution
RxNorm normalized name: NephrAmine 5.4% Essential Amino Acid Solution for Injection
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA solution will be administered 60 minutes prior to each Lu-177-DOTATATE infusion.
Trial: NCT04494958
Drug: Combination, Palbociclib + Binimetinib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will then start treatment with continuous oral binimetinib 45 mg/BID and palbociclib 100 mg daily, 21 days on / 7 days off, until disease progression. Study treatment will continue until disease progression.~If treatment tolerance is good, after a full cycle patients will be allowed to escalate palbociclib to 125 mg, according to the study investigators' decision. Alternatively, patients with non tolerable grade 2 events will resume at 30 mg/BID of binimetinib upon recovery, maintaining palbociclib at 100 mg 21-on/7-off. Depending on the side-effects, in case of clear relationship with palbociclib is established, palbociclib -instead of binimetinib - will be reduced to 75 mg daily.
Trial: NCT03816163
Drug: zolbetuximab
RxNorm normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an intravenous infusion.
Trial: NCT03816163
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as an intravenous infusion
Trial: NCT03816163
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as an intravenous infusion
Trial: NCT00863629
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.
Trial: NCT03540368
Drug: Tranexamic acid injection
RxNorm normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administering tranexamic acid loading dose 1 gram in 100 cc sodium chloride 0,9%, followed by maintenance dose 3 grams in infusion for 24 hours.
Trial: NCT00492401
Drug: decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02624050
Drug: Methohexital
RxNorm normalized name: Methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
Trial: NCT02624050
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
Trial: NCT03280550
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
Trial: NCT02147938
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02575482
Drug: SUVN-D4010
RxNorm normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01466725
Drug: CC-930
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00668525
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram low dose, oral administration, once daily dosing for 8 weeks.
Trial: NCT00668525
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram high dose, oral administration, once daily dosing for 8 weeks
Trial: NCT02088944
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT05694819
Drug: Darolutamide
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.
Trial: NCT05694819
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin at a dose of 3.6 mg will be administered subcutaneously every 4 weeks.
Trial: NCT02828319
Drug: Z-213
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
Trial: NCT00797927
Drug: quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: quetiapine (with equivalent dose to original antipsychotic agent) would replace the original antipsychotic agent for 28 days
Trial: NCT00538382
Drug: Artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.
Trial: NCT01084044
Drug: ulinastatin, saline solution
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
Trial: NCT00193310
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00193310
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02291718
Drug: Isovue
RxNorm normalized name: Isovue-370
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iodine contrast
Trial: NCT02222129
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02222129
Drug: liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00363025
Drug: Idarubicin versus daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03807778
Drug: Mobocertinib
RxNorm normalized name: Mobocertinib
DrugBank: Mobocertinib (DB16390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mobocertinib capsule.
Trial: NCT02131467
Drug: Perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral drug
Trial: NCT01233219
Drug: morphine chlorhydrate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an continuous infusion for 48h with morphine chlorhydrate 0,02 mg/kg/h.~Moreover, a rescue dose therapy will be prescribed with ketoprofen 160 mg or ketorolac 30mg (in case of allergy acetaminophene 1g) if NRS\<4 maximum x 3 daily.~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the infusion (T0) and the following 48h).
Trial: NCT03078725
Drug: Glyburide
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral hypoglycemic agent
Trial: NCT03078725
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral hypoglycemic agent
Trial: NCT01354691
Drug: ladostigil hemitartrate
RxNorm normalized name: Dihydrocodeine Bitartrate
DrugBank: Ladostigil (DB16213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.
Trial: NCT00277472
Drug: HCTZ
RxNorm normalized name: HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg taken once daily orally
Trial: NCT01781026
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single arm trial
Trial: NCT00259025
Drug: lipid emulsion with a high content of n-3 fatty acids
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00390364
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02255110
Drug: TH-302
RxNorm normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TH-302 will be administered at a dose of 300 milligram per square meter (mg/m\^2) by intravenous infusion over 30 minutes on Days 1 and 8 of every 21-day cycle until the evidence of significant treatment-related toxicity or progressive disease.
Trial: NCT03806595
Drug: Lidocaine 2% Injectable Solution
RxNorm normalized name: lidocaine 2% injectable solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Barre method of intranasal administration will be used to instil 1mL of lidocaine 2% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
Trial: NCT00717470
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT00717470
Drug: Simulect
RxNorm normalized name: Simulect
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral
Trial: NCT00717470
Drug: methylprednisolone / prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04493619
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin IV injection, 5 mg•min/mL
Trial: NCT02605863
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 160 mg by mouth daily for 12 months
Trial: NCT01394029
Drug: deferasirox
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00296348
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: immunosuppression
Trial: NCT00296348
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT00296348
Drug: daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral
Trial: NCT02002078
Drug: methylprednisolon
RxNorm normalized name: Methylprednisolon
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02980835
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate A and C contain 9 and 24 mL of ropivacaine HCl 0.5%, respectively.
Trial: NCT02980835
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectates A and C both contain 1 mL of dexamethasone 4mg/mL preparation.
Trial: NCT01266148
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
Trial: NCT01266148
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
Trial: NCT01266148
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study
Trial: NCT01266148
Drug: Anti Thymocyte Globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
Trial: NCT03723564
Drug: Lactated Ringers Solution for Injection
RxNorm normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using ultrasound guidance, a 22 gauge needle will be introduced into amniotic cavity. Warmed Lactated Ringers solution will be injected into the amniotic cavity until an AFI of 8.0 cm is achieved
Trial: NCT01269125
Drug: Leuprolide
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single injection of 3.75 leuprolide every 28 days, 3 dosages
Trial: NCT02135640
Drug: denosumab 60mg
RxNorm normalized name: DENOSUMAB 60MG/ML INJ
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: solution
Trial: NCT02135640
Drug: denosumab 120 mg
RxNorm normalized name: DENOSUMAB 120 MG/1.7 ML INJ
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: solution
Trial: NCT04646317
Drug: Dexmedetomidine injection
RxNorm normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infusion of dexmedetomidine will be prepared in Four syringes of 50ml containing dexmedetomidine in concentration of 1 microgram per millilitre.
Trial: NCT01060865
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg during the first two weeks , 300 mg for another 10 weeks
Trial: NCT00449059
Drug: acute infusion of nitroglycerine into the pulmonary artery
RxNorm normalized name: Sus scrofa artery preparation
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01040832
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab weekly (initial dose 400 milligram per square meter \[mg/m\^2\] over 120 minutes followed by 250 mg/m\^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.
Trial: NCT01040832
Drug: EMD 1201081
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 1201081 weekly (0.32 milligram per kilogram \[mg/kg\] by subcutaneous injection) will be administered in 3-week treatment cycle until disease progression. Subjects who will discontinue cetuximab due to toxicity in cetuximab monotherapy, could continue to receive EMD 1201081 monotherapy until disease progression. The total treatment period will be approximately 18 months.
Trial: NCT02385032
Drug: Ursodiol
RxNorm normalized name: Ursodiol
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02385032
Drug: URSO Forte
RxNorm normalized name: Urso Forte
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00127959
Drug: tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00127959
Drug: emtricitabine
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02517515
Drug: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
Trial: NCT03311178
Drug: Dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).